Treatment Strategies Targeting Amyloid -Protein
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
With the advent of the key discovery in the mid-1980s that the amyloid β-protein (Aβ) is the core constituent of the amyloid plaque pathology found in Alzheimer disease (AD), an intensive effort has been underway to attempt to mitigate its role in the hope of treating the disease. This effort fully matured when it was clarified that the Aβ is a normal product of cleavage of the amyloid precursor protein, and well-defined proteases for this process were identified. Further therapeutic options have been developed around the concept of anti-Aβ aggregation inhibitors and the surprising finding that immunization with Aβ itself leads to reduction of pathology in animal models of the disease. Here we review the progress in this field toward the goal of targeting Aβ for treatment and prevention of AD and identify some of the major challenges for the future of this area of medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…for pathology attributable to toxic effects of excess soluble Ab (Gong et al. 2003; Kayed et al. 2003; Lacor et al. 2004; Cleary et al. 2005; Lesne et al. 2006; Townsend et al. 2006b; Cheng et al. 2007; Walsh and Selkoe 2007; Klyubin et al. 2008; Shankar et al. 2008) as well as pathology…”
BackgroundRetractedProtein folding and misfolding
Dobson, C. M. (2003) · Nature · doi:10.1038/nature02261 · Cited by 4,791
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 2×
“First is the ample evidence for pathology attributable to toxic effects of excess soluble Ab (Gong et al. 2003; Kayed et al. 2003; Lacor et al. 2004; Cleary et al. 2005; Lesne et al. 2006; Townsend et al. 2006b; Cheng et al. 2007; Walsh and Selkoe 2007; Klyubin et al. 2008; Shankar et al. 2008) as…”
BackgroundVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“…enzyme) and its closely related homolog, BACE2, by a variety of approaches (Hussain et al. 1999, 2000; Saunders et al. 1999; Sinha et al. 1999; Vassar et al. 1999; Yan et al. 1999; Acquati et al. 2000; Bennett et al. 2000; Lin et al. 2000) delivered the second molecular target for discovery…”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 1×
“…caveat of current mouse models in the context of therapeutics targeting production of amyloid is that, in contrast to rare familial forms of AD (Scheuner et al. 1996), there is limited evidence that sporadic AD is a driven by overproduction of Ab (Fukumoto et al. 2002; Holsinger et al. 2002;…”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 1×
“5; Yang et al. 2005).”
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Indeed, evidence in support of the alternative possibility—that accumulation of b amyloid in sporadic AD results from reduced clearance and/or turnover of the peptide—has been reported (Mawuenyega et al. 2010).”
BackgroundBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 5×
“Plaque lowering appeared to be dependent on the antibody being able to recognize and bind aggregated Ab in the brain, as antibodies unable to bind to amyloid plaques in vitro had no significant impact on plaque pathology in vivo (Bard et al. 2000).”
BackgroundInfluentialSelf-citationAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 1×
“…soluble Ab (Gong et al. 2003; Kayed et al. 2003; Lacor et al. 2004; Cleary et al. 2005; Lesne et al. 2006; Townsend et al. 2006b; Cheng et al. 2007; Walsh and Selkoe 2007; Klyubin et al. 2008; Shankar et al. 2008) as well as pathology attributable to plaque-associated Ab (Spires et al. 2005;…”
BackgroundAmyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921 · cited 1×
“BACE Inhibitors The discovery of soluble Ab peptide in biological fluids (Haass et al. 1992; Seubert et al. 1992) consistent with the constitutive processing of APP was followed by a nearly decade-long effort to molecularly identify the responsible enzyme.”
BackgroundSelf-citationDeficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 1×
“…conclusive evidence to settle the argument, based on reverse genetic approaches supporting PS1 and PS2 as a critical component of g-secretase (De Strooper et al. 1998; Herreman et al. 1999, 2000; Steiner et al. 1999), that two transmembrane aspartyl residues in the presenilin amino-terminal…”
BackgroundIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · cited 1×
“BACE Inhibitors The discovery of soluble Ab peptide in biological fluids (Haass et al. 1992; Seubert et al. 1992) consistent with the constitutive processing of APP was followed by a nearly decade-long effort to molecularly identify the responsible enzyme.”
BackgroundSelf-citationMembrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438 · cited 1×
“…closely related homolog, BACE2, by a variety of approaches (Hussain et al. 1999, 2000; Saunders et al. 1999; Sinha et al. 1999; Vassar et al. 1999; Yan et al. 1999; Acquati et al. 2000; Bennett et al. 2000; Lin et al. 2000) delivered the second molecular target for discovery of drugs to inhibit…”
BackgroundAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“In eight of these progressing subjects who were autopsied, two showed no apparent decrease in plaque burden, four had intermediate decreases, and two had marked decreases (Holmes et al. 2008).”
BackgroundNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 3×
“…from the multidose phase 1 trial and was found to have had meningoencephalitis as detected by CD4þ T-cell infiltrates in the leptomeninges, most densely associated with amyloid laden blood vessels, as well as sparse lymphocyte infiltration in the cortex and perivascular spaces (Nicoll et al. 2003).”
BackgroundResultA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 2×
“…R-flurbuprofen) arose from cell culture experiments examining the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on APP processing (Weggen et al. 2001), which appeared to relate to epidemiological studies, suggesting a reduced prevalence of AD associated with prolonged use of…”
BackgroundSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“This trial was terminated early following four reports of acute meningoencephalitis that later were shown to have affected a total of 6% of all the actively immunized patients (18 out of 300; Orgogozo et al. 2003).”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 3×
“m266 has been shown to lower brain Ab levels in the CNS, although there are conflicting data in regard to its ability to clear amyloid pathology from the brains of APP transgenic animals (DeMattos et al. 2001; Seubert et al. 2008).”
BackgroundRisk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., et al. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0811 · Cited by 1,080
Rationalization of the effects of mutations on peptide andprotein aggregation rates
Chiti, F., Stefani, M., Taddei, N., Ramponi, G., & Dobson, C. M. (2003) · Nature · doi:10.1038/nature01891 · Cited by 1,072 · cited 2×
“One significant step forward was the development of a model with high predictive value by Dobson and colleagues (Chiti et al. 2003).”
BackgroundGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 1×
“First is the ample evidence for pathology attributable to toxic effects of excess soluble Ab (Gong et al. 2003; Kayed et al. 2003; Lacor et al. 2004; Cleary et al. 2005; Lesne et al. 2006; Townsend et al. 2006b; Cheng et al. 2007; Walsh and Selkoe 2007; Klyubin et al. 2008; Shankar et al. 2008) as…”
BackgroundLuo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987 · cited 1×
“…et al. 2004; Cleary et al. 2005; Lesne et al. 2006; Townsend et al. 2006b; Cheng et al. 2007; Walsh and Selkoe 2007; Klyubin et al. 2008; Shankar et al. 2008) as well as pathology attributable to plaque-associated Ab (Spires et al. 2005; Kuchibhotla et al. 2008; Meyer-Luehmann et al. 2008, 2009).”
BackgroundSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954 · cited 1×
“First is the ample evidence for pathology attributable to toxic effects of excess soluble Ab (Gong et al. 2003; Kayed et al. 2003; Lacor et al. 2004; Cleary et al. 2005; Lesne et al. 2006; Townsend et al. 2006b; Cheng et al. 2007; Walsh and Selkoe 2007; Klyubin et al. 2008; Shankar et al. 2008) as…”
BackgroundPhotoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., et al. (2000) · Nature · doi:10.1038/35015085 · Cited by 866
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · cited 2×
“…variety of cognition assays independent of plaque clearance, suggesting that mechanisms such as sequestration of toxic soluble Ab species may be critical for improving behavioral deficits observed in transgenic mouse models of AD (Dodart et al. 2002; Kotilinek et al. 2002; Sigurdsson et al. 2004).”
BackgroundLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Saura, C. A., Choi, S.-Y., Beglopoulos, V., Malkani, S., Zhang, D., Rao, B. S. S., Chattarji, S., Kelleher, R. J., Kandel, E. R., Duff, K., et al. (2004) · Neuron · doi:10.1016/s0896-6273(04)00182-5 · Cited by 757 · cited 2×
“A decline in cognition of patients on drug relative to placebo, as well the emergence of skin neoplasms in the LY-450139 phase 3 study, noted in the press release announcing early termination of the trial, are reminiscent of phenotypes noted in partial or conditional PS loss of function models (Fig. 4; Saura et al. 20…”
BackgroundA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Self-citationElevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729
Roberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“Knockout mouse models provided in vivo validation of the longsuspected pivotal role forb-secretase in Ab production and the apparent safety of this target based on the relatively benign phenotype of BACE1-deficient mice (Cai et al. 2001; Luo et al. 2001, 2003; Roberds et al. 2001).”
BackgroundControl of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · cited 1×
“…of BACE1, as well as BACE1/BACE2 double KO mice, however, revealed roles for this enzyme in cellular pathways involved in myelination and behavior (Harrison et al. 2003; Dominguez et al. 2005; Laird et al. 2005; Hu et al. 2006; Willem et al. 2006; Kobayashi et al. 2008; Savonenko et al. 2008).”
BackgroundRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Self-citationNSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634 · cited 3×
“In a 21-d study in healthy elderly (55–80 year) volunteers given placebo, 400, 800, or 1600 mg/d in a twice-per-day regimen, R-flurbuprofen was safe and well tolerated, and displayed dose-dependent pharmacokinetics in brain and plasma with respect to Cmax, whereas exposure in plasma appeared 6 Cite this article as Col…”
BackgroundInfluentialKuchibhotla, K. V., Goldman, S. T., Lattarulo, C. R., Wu, H.-Y., Hyman, B. T., & Bacskai, B. J. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.008 · Cited by 614 · cited 1×
“…et al. 2004; Cleary et al. 2005; Lesne et al. 2006; Townsend et al. 2006b; Cheng et al. 2007; Walsh and Selkoe 2007; Klyubin et al. 2008; Shankar et al. 2008) as well as pathology attributable to plaque-associated Ab (Spires et al. 2005; Kuchibhotla et al. 2008; Meyer-Luehmann et al. 2008, 2009).”
BackgroundBace1 modulates myelination in the central and peripheral nervous system
Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D., & Yan, R. (2006) · Nature Neuroscience · doi:10.1038/nn1797 · Cited by 608 · cited 2×
“Subsequent characterization of BACE1, as well as BACE1/BACE2 double KO mice, however, revealed roles for this enzyme in cellular pathways involved in myelination and behavior (Harrison et al. 2003; Dominguez et al. 2005; Laird et al. 2005; Hu et al. 2006; Willem et al. 2006; Kobayashi et al. 2008; Savonenko et al. 200…”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563
Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease
Holsinger, R. M. D., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002) · Annals of Neurology · doi:10.1002/ana.10208 · Cited by 562
Spires, T. L., Meyer-Luehmann, M., Stern, E. A., McLean, P. J., Skoch, J., Nguyen, P. T., Bacskai, B. J., & Hyman, B. T. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1879-05.2005 · Cited by 550 · cited 2×
“…et al. 2004; Cleary et al. 2005; Lesne et al. 2006; Townsend et al. 2006b; Cheng et al. 2007; Walsh and Selkoe 2007; Klyubin et al. 2008; Shankar et al. 2008) as well as pathology attributable to plaque-associated Ab (Spires et al. 2005; Kuchibhotla et al. 2008; Meyer-Luehmann et al. 2008, 2009).”
BackgroundEffects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · cited 5×
“For example, increased removal of amyloid deposits, changes in plaque composition or changes in CSF dynamics resulting from increased Ab outflow could each alter the water content of the brain, resulting in an apparent loss of brain volume (Fox et al. 2005).”
BackgroundInfluentialLaird, F. M., Cai, H., Savonenko, A. V., Farah, M. H., He, K., Melnikova, T., Wen, H., Chiang, H.-C., Xu, G., Koliatsos, V. E., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-05.2005 · Cited by 521
Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., & Ihara, Y. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2362-09.2009 · Cited by 498
Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489 · cited 2×
“Both approaches also rescue the abnormal hippocampal synaptic plasticity that occurs in rodents exposed to soluble Ab oligomers (Klyubin et al. 2005).”
BackgroundAmyloid-β immunotherapy for Alzheimer's disease: the end of the beginning
Schenk, D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn938 · Cited by 436
Self-citationReversible memory loss in a mouse transgenic model of Alzheimer’s disease
Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., & Ashe, K. H. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06331.2002 · Cited by 420 · cited 2×
“…variety of cognition assays independent of plaque clearance, suggesting that mechanisms such as sequestration of toxic soluble Ab species may be critical for improving behavioral deficits observed in transgenic mouse models of AD (Dodart et al. 2002; Kotilinek et al. 2002; Sigurdsson et al. 2004).”
BackgroundA Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402 · cited 2×
“2000), consistent with the epidemiological studies, prospective treatment studies of NSAIDs in mild–moderate AD failed to show benefit on primary outcome measures (Aisen et al. 2003; Thal et al. 2005).”
ResultFormation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia
Grathwohl, S. A., Kälin, R. E., Bolmont, T., Prokop, S., Winkelmann, G., Kaeser, S. A., Odenthal, J., Radde, R., Eldh, T., Gandy, S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2432 · Cited by 401
Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease
Monsonego, A., Zota, V., Karni, A., Krieger, J. I., Bar-Or, A., Bitan, G., Budson, A. E., Sperling, R., Selkoe, D. J., & Weiner, H. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318104 · Cited by 367 · cited 1×
“The principal T-cell epitopes on Ab have been mapped to its carboxyl terminus (Glaser et al. 1998; Monsonego et al. 2003) and can therefore be avoided by immunizing with Ab sequences devoid of these T-cell epitopes in the next generation of active vaccines.”
BackgroundEvaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356 · cited 1×
“No treatment differences were observed across efficacy measures in this safety trial, apart from less decline on the Disability Assessment of Dementia scores in active versus placebo treated patients (Bayer et al. 2005).”
BackgroundNon-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323
Self-citationA γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322 · cited 1×
“…in the studies cited above, a decline in the rate of synthesis of brain Ab, monitored in CSF using a novel stable isotope labeling kinetic method, was effected by semagacestat in a dose-responsive manner in healthy volunteers given single doses of 100, 140, or 280 mg of drug (Bateman et al. 2009).”
MethodKlyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5161-07.2008 · Cited by 321 · cited 1×
“…2003; Kayed et al. 2003; Lacor et al. 2004; Cleary et al. 2005; Lesne et al. 2006; Townsend et al. 2006b; Cheng et al. 2007; Walsh and Selkoe 2007; Klyubin et al. 2008; Shankar et al. 2008) as well as pathology attributable to plaque-associated Ab (Spires et al. 2005; Kuchibhotla et al. 2008;…”
BackgroundRacke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
Expression Analysis of BACE2 in Brain and Peripheral Tissues
Bennett, B. D., Babu-Khan, S., Loeloff, R., Louis, J.-C., Curran, E., Citron, M., & Vassar, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002688200 · Cited by 317 · cited 2×
“The simultaneous reports of cloning BACE1 (b-site APP cleaving enzyme) and its closely related homolog, BACE2, by a variety of approaches (Hussain et al. 1999, 2000; Saunders et al. 1999; Sinha et al. 1999; Vassar et al. 1999; Yan et al. 1999; Acquati et al. 2000; Bennett et al. 2000; Lin et al. 2000) delivered the se…”
BackgroundMcConlogue, L., Buttini, M., Anderson, J. P., Brigham, E. F., Chen, K. S., Freedman, S. B., Games, D., Johnson-Wood, K., Lee, M., Zeller, M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611687200 · Cited by 300 · cited 1×
“Delayed onset of AD pathology in APP BACE1þ/2 mice suggest that, as with GSIs, partial inhibition of BACE1 may be a solution toward mitigating the potential safety issues associated with inhibiting this protease (Laird et al. 2005; McConlogue et al. 2007).”
BackgroundSavonenko, A. V., Melnikova, T., Laird, F. M., Stewart, K.-A., Price, D. L., & Wong, P. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710373105 · Cited by 290
A Three-Stage Kinetic Model of Amyloid Fibrillation
Lee, C.-C., Nayak, A., Sethuraman, A., Belfort, G., & McRae, G. J. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.098608 · Cited by 278 · cited 1×
“The early step is termed the latency phase (Lee et al. 2007).”
Aβ Species Removal After Aβ 42 Immunization
Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265
Self-citationWilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232 · cited 1×
“Furthermore, microglial-mediated phagocytosis of plaques required antibody binding to the amyloid plaque itself rather than to fibrillar or oligomeric Ab species (Bard et al. 2000; Wilcock et al. 2003, 2004).”
BackgroundRodríguez-Rodríguez, C., Sánchez de Groot, N., Rimola, A., Álvarez-Larena, Á., Lloveras, V., Vidal-Gancedo, J., Ventura, S., Vendrell, J., Sodupe, M., & González-Duarte, P. (2009) · Journal of the American Chemical Society · doi:10.1021/ja806062g · Cited by 210 · cited 1×
“…al. 1999; Reixach et al. 2000; Thomas et al. 2001; Ono et al. 2002, 2004; Khurana et al. 2003; Blanchard et al. 2004; Hirohata et al. 2005; Fujiwara et al. 2006; Kokkoni et al. 2006; Durairajan et al. 2008; Ryu et al. 2008; Wiesehan et al. 2008; Hong et al. 2009; Rodriguez-Rodriguez et al. 2009).”
BackgroundBrendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190
Barten, D. M., Guss, V. L., Corsa, J. A., Loo, A., Hansel, S. B., Zheng, M., Munoz, B., Srinivasan, K., Wang, B., Robertson, B. J., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075408 · Cited by 159
Harrison, S. M., Harper, A. J., Hawkins, J., Duddy, G., Grau, E., Pugh, P. L., Winter, P. H., Shilliam, C. S., Hughes, Z. A., Dawson, L. A., et al. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00227-6 · Cited by 152
Self-citationAmyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations
Lombardo, J. A., Stern, E. A., McLellan, M. E., Kajdasz, S. T., Hickey, G. A., Bacskai, B. J., & Hyman, B. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10879.2003 · Cited by 149
Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease
Yates, P. A., Sirisriro, R., Villemagne, V. L., Farquharson, S., Masters, C. L., Rowe, C. C., & For the AIBL Research Group (2011) · Neurology · doi:10.1212/wnl.0b013e318221ad36 · Cited by 130
Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., & Iwatsubo, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2021-09.2009 · Cited by 117 · cited 1×
“…a recent report has questioned the “peripheral sink” hypothesis by studying the dynamics and efflux of 125I-labeled Ab from the CNS and suggesting that peripherally administered m266 sequesters soluble Ab in the brain, resulting in a reduced rather than enhanced Ab efflux (Yamada et al. 2009).”
BackgroundSelf-citationAisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Cited by
The amyloid state and its association with protein misfolding diseases.
Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3810 · Cited by 2,382
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075
Epidemiology of Alzheimer Disease
Mayeux, R., & Stern, Y. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006239 · Cited by 1,064
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Metadata
- Authors
- Schenk, D., Basi, G. S., & Pangalos, M. N.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-05-15
- Volume
- 2
- Issue
- 9
- Pages
- a006387-a006387
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2109550688
- Cited by
- 126
- References
- 76
- Type
- posted content
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.